fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

TOURMALINE-MM3 study

Written by | 28 Sep 2019

Professor Kwee Yong (London, UK) details the results from the Tourmaline-MM3 study.

Advances in RRMM

Written by | 9 May 2019

Professor Kwee Yong (London, UK) details the results from the Tourmaline-MM3 study

Transplantation, Consolidation and Maintenance

Written by | 8 May 2019

  Autologous stem cell transplantation (ASCT) remains the standard of care option for those patients with newly-diagnosed multiple myeloma (MM) who are eligible for and able to tolerate… read more.

Integrating CAR T-Cell therapy into the treatment of myeloma

Written by | 7 May 2019

Professor Julie Vose (Nebraska, USA) updates us on the current status of BCMA CAR T-cell therapy.

State of the art clinical trials

Written by | 6 May 2019

Professor Sagar Lonial (Atlanta, USA) opened the UKMF by discussing the latest evidence in the management of myeloma, with comment from session chair Professor Gordon Cook (Leeds, UK).

Highlights from ASH 2018

Written by | 14 Feb 2019

As usual, ASH provided lots of exciting updates in the management of lymphoma. One particularly interesting study from which data was presented at ASH was the ECHELON-2 study,… read more.

ASH 2018: Advances in the management of peripheral T-cell lymphoma

Written by | 5 Feb 2019

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies that often fails to respond to standard of care treatment,1-3 and the need for new therapies is… read more.

ASH 2018: Phoenix and other DLBCL study updates

Written by | 5 Feb 2019

Professor Anas Younes (New York, USA) and Dr Andrew Davies (Southampton, UK) discuss the outcomes from the Pheonix study, with Professor Anas Younes (New York, USA) highlighting future… read more.

ASH 2018: Advances in RRMM

Written by | 25 Jan 2019

Relapsed and refractory MM continues to challenge clinicians and several oral abstracts at ASH 2018 presented new and updated data on delaying disease progression and prolonging survival after… read more.

ASH 2018: TOURMALINE-MM3 study

Written by | 25 Jan 2019

Article written by Maria Dalby. Interview by Hannah Chatfield. Professor Kwee Yong (London, UK), Dr Martin Kaiser (London, UK) and Professor Gareth Morgan (Arkansas, USA) discuss the results from the Tourmaline-MM3 study and… read more.

ASH 2018: Novel agents in combination for relapsed/refractory Hodgkin’s lymphoma: the ECOG-ACRIN E4412 study

Written by | 14 Jan 2019

Article written by Maria Dalby. Interviews by Hannah Chatfield. Immune checkpoints such as CTLA-4 and PD-1 are known to play a vital part in anti-tumour T-cell function in… read more.

ASH 2018: Hodgkin lymphoma: beyond ABVD for everyone

Written by | 14 Jan 2019

Article by Maria Dalby. Interviews by Hannah Chatfield Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.